Zhang Ling, Gao Lifang, Li Yang, Lin Guimiao, Shao Yueting, Ji Kun, Yu Hao, Hu Jiadi, Kalvakolanu Dhananjaya V, Kopecko Dennis J, Zhao Xuejian, Xu De-Qi
Prostate Diseases Prevention and Treatment Research Center and Department of Pathophysiology, School of Basic Medicine, Jilin University, Changchun, PR China.
Clin Cancer Res. 2008 Jan 15;14(2):559-68. doi: 10.1158/1078-0432.CCR-07-1176.
Persistent activation of signal transducers and activators of transcription 3 (Stat3) and its overexpression contribute to the progression and metastasis of several different tumor types. For this reason, Stat3 is a reasonable target for RNA interference-mediated growth inhibition. Blockade of Stat3 using specific short hairpin RNAs (shRNA) can significantly reduce prostate tumor growth in mice. However, RNA interference does not fully ablate target gene expression in vivo, owing to the idiosyncrasies associated with shRNAs and their targets. To enhance the therapeutic efficacy of Stat3-specific shRNA, we applied a combination treatment involving gene associated with retinoid-IFN-induced mortality 19 (GRIM-19), another inhibitor of STAT3, along with shRNA.
The coding sequences for GRIM-19, a cellular STAT3-specific inhibitor, and Stat3-specific shRNAs were used to create a dual expression plasmid vector and used for prostate cancer therapy in vitro and in mouse xenograft models in vivo.
The coexpressed Stat3-specific shRNA and GRIM-19 synergistically and more effectively suppressed prostate tumor growth and metastases when compared with treatment with either single agent alone.
The simultaneous use of two specific, but mechanistically different, inhibitors of STAT3 activity exerts enhanced antitumor effects.
信号转导子和转录激活子3(Stat3)的持续激活及其过表达促进了几种不同肿瘤类型的进展和转移。因此,Stat3是RNA干扰介导的生长抑制的合理靶点。使用特异性短发夹RNA(shRNA)阻断Stat3可显著降低小鼠前列腺肿瘤的生长。然而,由于与shRNA及其靶点相关的特性,RNA干扰并不能在体内完全消除靶基因的表达。为提高Stat3特异性shRNA的治疗效果,我们应用了一种联合治疗方法,将视黄酸-干扰素诱导死亡率19(GRIM-19)相关基因(另一种STAT3抑制剂)与shRNA联合使用。
使用细胞STAT3特异性抑制剂GRIM-19和Stat3特异性shRNA的编码序列构建双表达质粒载体,并用于体外前列腺癌治疗和体内小鼠异种移植模型。
与单独使用单一药物治疗相比,共表达的Stat3特异性shRNA和GRIM-19协同且更有效地抑制了前列腺肿瘤的生长和转移。
同时使用两种特异性但作用机制不同的STAT3活性抑制剂可增强抗肿瘤效果。